Sanofi (NASDAQ:SNY) Shares Sold by Hilltop National Bank

Hilltop National Bank cut its position in Sanofi (NASDAQ:SNYFree Report) by 4.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,377 shares of the company’s stock after selling 472 shares during the period. Hilltop National Bank’s holdings in Sanofi were worth $549,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Barrow Hanley Mewhinney & Strauss LLC grew its stake in shares of Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after purchasing an additional 3,164,092 shares during the period. Franklin Resources Inc. boosted its stake in shares of Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after acquiring an additional 395,744 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in Sanofi by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after purchasing an additional 246,224 shares during the period. Federated Hermes Inc. grew its holdings in Sanofi by 26.5% in the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after purchasing an additional 673,172 shares during the period. Finally, Natixis Advisors LLC increased its position in shares of Sanofi by 4.1% in the third quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock valued at $165,640,000 after buying an additional 114,133 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on SNY shares. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

View Our Latest Research Report on SNY

Sanofi Price Performance

Shares of NASDAQ:SNY traded down $0.26 during midday trading on Friday, hitting $48.97. The company had a trading volume of 602,779 shares, compared to its average volume of 1,990,278. The business’s 50-day simple moving average is $48.79 and its 200-day simple moving average is $52.07. The stock has a market cap of $124.28 billion, a price-to-earnings ratio of 24.98, a price-to-earnings-growth ratio of 1.23 and a beta of 0.57. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNYGet Free Report) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the previous year, the firm earned $2.55 EPS. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, research analysts predict that Sanofi will post 4.06 earnings per share for the current year.

Sanofi Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Recommended Stories

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.